75
Views
0
CrossRef citations to date
0
Altmetric
Letter to the Editor

Letter to the Editor: COVID-19 utilization of ACE-2 receptor to enter the host cell

References

  • Hendaus, M. A. (2020). Remdesivir in the treatment of coronavirus disease 2019 (COVID-19): A simplified summary. Journal of Biomolecular Structure & Dynamics, 1–6. https://doi.org/10.1080/07391102.2020.1767691
  • Hendaus, M. A., & Jomha, F. A. (2020). From COVID-19 to clot: The involvement of the complement system. Journal of Biomolecular Structure & Dynamics, 1–6. https://doi.org/10.1080/07391102.2020.1832919
  • Li, Y., Zhang, Z., Yang, L., Lian, X., Xie, Y., Li, S., Xin, S., Cao, P., & Lu, J. (2020). The MERS-CoV receptor DPP4 as a candidate binding target of the SARS-CoV-2 spike. iScience, 23(8), 101400. https://doi.org/10.1016/j.isci.2020.101400
  • Seyedpour, S., Khodaei, B., Loghman, A. H., Seyedpour, N., Kisomi, M. F., Balibegloo, M., Nezamabadi, S. S., Gholami, B., Saghazadeh, A., & Rezaei, N. (2021). Targeted therapy strategies against SARS-CoV-2 cell entry mechanisms: A systematic review of in vitro and in vivo studies. Journal of Cellular Physiology, 236(4), 2364–2392. https://doi.org/10.1002/jcp.30032
  • Strollo, R., & Pozzilli, P. (2020). DPP4 inhibition: Preventing SARS-CoV-2 infection and/or progression of COVID-19? Diabetes/Metabolism Research and Reviews, 36(8), e3330. https://doi.org/10.1002/dmrr.3330

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.